WuXi Healthcare Ventures is a Chinese investment firm that helps life sciences companies to develop transformative therapies.
Business Model:
Revenue: $0
Employees: 0-0
Address: 288 Fute Zhong Road
City: Shanghai
State: shanghai municipality
Zip: 200131
Country: CN
Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2015 | Hua Medicine | Series B | 0 |
8/2016 | Nutrinia | Series D | 30M |
2/2017 | Forerunner Medical | Series B | - |
3/2018 | IDEAYA Biosciences | Series B | 0 |
10/2015 | 23andMe | Series E | 115M |
9/2014 | Avelas Biosciences | Series B | 7.4M |
9/2017 | XW Laboratories | Series B | 0 |
3/2021 | Zenas BioPharma | Series A | - |
1/2016 | Refuge Biotechnologies | Series A | 8.9M |
1/2015 | UNITY Biotechnology | Series A | 2.3M |
1/2021 | LifeMine Therapeutics | Series B | 0 |
5/2016 | IDEAYA Biosciences | Series A | 46M |
7/2014 | IMPACT Therapeutics | Series A | - |
7/2021 | Adlai Nortye | Series D | 0 |
2/2019 | Halda Therapeutics | Series A | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
1/2016 | Syros Pharmaceuticals | Series C | 40M |
1/2016 | Forerunner Medical | Series A | 9.1M |
9/2020 | XW Laboratories | Series C | 0 |
8/2016 | Avelas Biosciences | Series C | 0 |
1/2015 | Vivace | Series A | 15M |
6/2017 | Vivace Therapeutics | Series B | 25M |
1/2016 | Twist Bioscience | Series D | 61M |
3/2017 | Ivenix | Venture Round | 50M |
9/2016 | TenNor Therapeutics | Series B | 25M |
5/2018 | Refuge Biotechnologies | Series B | 0 |
9/2015 | Tunitas Therapeutics, Inc. | Series A | 10M |
4/2016 | Hua Medicine | Series C | 0 |
10/2014 | Syros Pharmaceuticals | Series B | 53M |
1/2019 | Antengene Corporation | Series B | 0 |
11/2015 | Lumo Bodytech | Series B | 10M |
11/2017 | Medeor Therapeutics | Series B | 0 |
9/2015 | Ivenix | Venture Round | 0 |
9/2011 | Hua Medicine | Series A | 50M |
12/2014 | Adagene | Series A | 8M |
12/2015 | AltheaDx | Series C | 30M |
1/2016 | Adagene | Series B | 0 |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
7/2021 | Adlai Nortye | Series D | 0 |
1/2021 | LifeMine Therapeutics | Series B | 0 |
9/2020 | XW Laboratories | Series C | 0 |
2/2019 | Halda Therapeutics | Series A | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
5/2018 | Refuge Biotechnologies | Series B | 0 |
3/2018 | IDEAYA Biosciences | Series B | 0 |
11/2017 | Medeor Therapeutics | Series B | 0 |
9/2017 | XW Laboratories | Series B | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|